Acute coronary syndromes result from fissure, erosion or rupture of a vulnerable atherosclerotic plaque. The characteristics of a vulnerable plaque include a large lipid pool, an abundance of inflammatory cells and mediators, a reduced smooth muscle cell and collagen content and a thin overlying fibrous cap. Potential therapeutic strategies at achieving plaque stabilization have targeted these features. Lipid lowering agents, b-adrenergic blockers, angiotensin converting enzyme inhibitors and antioxidants have been shown to reduce the incidence of acute coronary syndromes, presumably through plaque stabilization. Matrix metalloproteinase inhibitors as well as macrolide antibiotics and gene therapy approaches show promise in achieving plaque stabilization. The evidence supporting plaque stabilization by these agents and the mechanisms by which these agents stabilize plaques are discussed in detail in this review.
Introduction
stenosed (,50%) on a prior recent angiogram [19] [20] [21] [22] [23] . This concept is supported by the demonstration of a mild Acute coronary syndromes, including unstable angina, residual stenosis on angiography after thrombolytic therapy acute myocardial infarction and sudden cardiac death, for an acute myocardial infarction [22, [24] [25] [26] . The severiresult from fissure, erosion or frank rupture of a vulnerable ty of stenosis on coronary angiography poorly predicts the atherosclerotic plaque [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The clinical manifestations propensity of a lesion to rupture. of plaque disruption depend on the extent of thrombus The intrinsic features that characterize a plaque as formation. An acute coronary syndrome will occur only if vulnerable are an increased lipid content, an increased coronary blood flow is reduced and collateral flow is macrophage, foam cell and T lymphocyte content, and a inadequate [16] . Most arterial wall cracks in the coronaries reduced collagen and smooth muscle cell content [5, 6, 27 are asymptomatic and do not result in arterial occlusion . 32] . Rupture tends to occur at the margins or 'shoulder Plaque ruptures can be found in 9% of all subjects and in region' of plaques where the overlying fibrous cap is 22% of patients with diabetes or hypertension who died of necrotic, very thin and extensively infiltrated by macrononcardiac causes [17] . It is likely that many lesions grow phages and adjacent to relatively normal tissue [1,4,33-through plaque rupture, mural thrombus and remodeling of 35]. The 'shoulder region' is the site exposed to the the plaque. Therefore, plaque stabilization may not only greatest shear stress [36] . The extracellular lipid pool reduce the incidence of acute coronary syndromes but also within a plaque decreases load-bearing capabilities due to prevent the evolution of plaques to more stenotic lesions poor tensile strength and results in increased stress else- [18] .
where in the vessel wall, specifically the overlying fibrous In the majority of patients presenting with acute corcap [37] . onary syndromes, the culprit lesion was not significantly The extrinsic features that cause a vulnerable plaque to rupture include increased blood pressure or vasospasm [23, [38] [39] [40] . Acute myocardial infarction has been associvasodilator properties could benefit ischemia. The recovery ated with trigger events, including emotional stress and of endothelial dysfunction and improved vasomotor funcphysical activity [41] [42] [43] [44] [45] [46] . Both emotional and physical tion following lipid-lowering therapy could also limit stress may contribute to myocardial infarction by increasvasospasm that accompanies plaque rupture, decrease ing blood pressure and by inducing coronary vasospasm.
recruitment of inflammatory cells and promote fibrinolysis. In animal models, a sudden rise in arterial pressure can The improvement in endothelium-dependent vasomotor produce plaque rupture in the presence of endothelial function occurs rapidly after lipid lowering, in only a damage [1] . Despite this, most cardiac events occur matter of weeks following effective pharmacotherapy [55] . without an identifiable trigger [47] .
The second hypothesis to explain the discrepancy bePotential therapeutic strategies to achieve plaque stabilitween the magnitude of the angiographic and clinical zation, resulting in a reduced incidence of acute coronary benefit of the regression trials is that lipid-lowering alters syndromes, have targeted these intrinsic or extrinsic feaintimal plaque stability in an endothelium-independent tures that promote plaque rupture. Lipid lowering agents, manner. Lipids in the atheroma not only create mechanical antioxidants, b-adrenergic blockers and angiotensin coninstability, but also biologically active lipids participate in verting enzyme inhibitors have been shown to reduce the promoting oxidative stress and inflammatory responses incidence of acute coronary syndromes, presumably such as monocyte migration. Lipid-lowering may therefore through plaque stabilization. Strategies promoting extracelinfluence the matrix degradation cascade that appears most lular matrix synthesis or preventing degradation within the active in macrophage-rich areas of the atheroma, as well as plaque, as well as more novel gene therapy approaches, promote mechanical stability within the plaque. After may show promise in achieving plaque stabilization.
plaque disruption, the highly thrombogenic components of a lipid-rich core increase the subsequent risk of the formation of a potentially occlusive thrombus [58] .
Lipid lowering agents
With regard to mechanical stability, the larger and the softer the lipid core of the plaque, the more stress the In angiographic regression studies of lipid-lowering overlying fibrous cap must bear. Plaque lipid content therapies, a small degree of plaque regression has been decreases after a reduction in serum cholesterol levels in associated with a more substantial reduction in the incianimal models [59] . Lowering of serum LDL cholesterol dence of clinical cardiac events (Table 1) [13, [48] [49] [50] . For leads to a reduction in the amount of cholesterol entering a review of these trials, see references [51, 50] In these the plaque and, more importantly, an increase in serum studies, lipid lowering therapy included hydroxyhigh density lipoprotein (HDL) cholesterol may contribute methylglutaryl coenzyme A (HMG CoA) reductase into active LDL removal from the vessel wall and from the hibitors, niacin, bile acid resins, fibrates, low density macrophage or foam cell [60, 61] . By inhibiting the oxidalipoprotein (LDL) apheresis, diet and exercise, and partial tion of LDL, HDL may protect against excessive lipid ileal bypass. In general, these studies have demonstrated entry into the vessel wall. Removal of lipid increases the that an improvement in the lipid profile with treatment was plaque's relative collagen content and increases the proassociated with a modest retardation of angiographic duction of collagen, favoring plaque stabilization [62] . disease progression and a more marked reduction in Autopsy examination of the hearts of 113 men with clinical cardiac events. The two dominant hypotheses to coronary disease who had died suddenly revealed that an explain the discrepancy between the magnitude of the elevated total LDL to HDL cholesterol ratio was associated angiographic and clinical benefit of cholesterol reduction with rupture of vulnerable plaques and that a strong therapy are plaque stabilization and improved endothelial correlation existed between serum cholesterol and the function [52, 53] . One or both mechanisms may play a role number of vulnerable plaques in the coronary arteries [15] . in the clinical benefit seen with the lipid-lowering Lipid lowering may stabilize plaques by reducing the therapies.
expression and activity of matrix-degrading enzymes, Elevated LDL levels have been associated with reduced favoring collagen accumulation in the fibrous cap, making endothelial function, presumably secondary to decreased it more resistant to rupture. In an experimental hypernitric oxide, a potent endogenous vasodilator produced by cholesterolemic rabbit model, reduction in serum cholesvascular endothelial cells. A reduction in the LDL levels terol by cessation of the atherogenic diet resulted in a using lipid-lowering drugs has resulted in improved endomarked decrease in the macrophage-derived foam cell thelial function [52, 54, 55] . Oxidized LDL downregulates content within the atheroma and a resultant decrease in the endothelial cell nitric oxide synthase (ecNOS), the enzyme macrophage-derived matrix-degrading enzymes (the matrix converting L-arginine to nitric oxide [56] . HMG CoA metalloproteinases MMP-1, MMP-2, MMP-3 and MMPreductase inhibitors not only restore endothelial function 9). The decrease in matrix-degrading enzymes was associby reducing oxidized LDL cholesterol levels, but also by ated with a substantial accumulation of interstitial collagen directly upregulating ecNOS activity through an increase in the intima of the atherosclerotic lesions within the in ecNOS mRNA stability [57] . Restoration of endothelial rabbits [63] . Cholesterol lowering therapies may also change the Survival Study (4S) [72] and the Cholesterol and Reproportion of the constituents of the lipid core, promoting current Events Study (CARE) [73] , have confirmed the plaque stabilization. Plaques that undergo disruption tend reduction in mortality and coronary events using the HMG to be relatively soft containing a high concentration of CoA reductase inhibitors (Table 2 ). cholesterol esters, rather than of free cholesterol monohydrate crystals [58, [64] [65] [66] . In experimental cholesterol-lowering studies, cholesterol esters were converted to insolu-3. Antioxidants ble cholesterol monohydrate crystals, resulting in a stiffer lipid core that was more resistant to plaque rupture [66, 67] .
The oxidation of LDL cholesterol increases its incorpo-HMG CoA reductase inhibitors may also achieve plaque ration into the arterial intima during atherogenesis. Oxistabilization through effects that are independent of their dized LDL binds to the scavenger cell receptor on monocholesterol-lowering properties. Using an atherosclerotic cyte-derived macrophages and contributes to foam cell nonhuman primate model, treatment with pravastatin as formation. As discussed above, oxidized LDL impairs compared with an adjustable diet to maintain identical total endothelial-dependent vasodilatation and generates an incholesterol and HDL levels revealed no difference in the flammatory response by increasing monocyte adhesion to plaque size of coronary arteries by histology. However, endothelial cells, enhancing monocyte chemotaxis, and treatment with pravastatin did demonstrate improved vasoinhibiting tissue macrophage motility. Oxidized LDL also motor function in response to acetylcholine and reduced modifies the functional response of vascular smooth musmacrophage content in the intima and media, consistent cle cells to angiotensin II stimulation, as well as promoting with plaque stabilization [68] . These findings were inthrombus formation through its inhibition of the nitric dependent of the lipid-lowering effects since the diet group oxide synthase activity of platelets and through its enhad the same cholesterol levels as the pravastatin group by hancement of tissue factor expression by monocytes [74] . study design. The mechanism by which macrophage Antioxidants, through their inhibition of LDL oxidation, content is reduced with pravastatin in this study may be may contribute to plaque stabilization. related to the adhesiveness of circulating monocytes for Antioxidants may also promote plaque stabilization by endothelial cells of an atherosclerotic plaque. Humans with reducing matrix degradation within the plaque. In an hypercholesterolemia have increased adhesiveness of isoexperimental hypercholesterolemic rabbit model, treatment lated monocytes to fixed endothelial cells in vitro, a with a reactive oxygen species (ROS) scavenger, N-acetylresponse that is diminished with lovastatin and simvastatin cysteine, markedly decreased the expression and activation [69] . Hypercholesterolemic rats treated with fluvastatin of the macrophage-derived matrix-degrading enzyme have significantly attenuated leukocyte-adherence re-MMP-9 [75] . ROSs can trigger activation of MMP presponses to platelet activation factor and leukotriene B cursors, which may relate to the mechanism by which 4 [69] . N-acetyl-cysteine decreases MMP-9 activation [76] , but The larger non-angiographic clinical trials of primary the mechanism by which it affects MMP-9 expression is and secondary prevention, including the West of Scotland unclear. Treatment with other antioxidants (probucol and Coronary Prevention Study (WOSCOPS) [70] , the Air vitamins E and C) have been shown to reduce intimal Force / Texas Coronary Atherosclerosis Prevention Study lesions after balloon injury in hypercholesterolemic ani-(AFCAPS / TexCAPS) [71] , the Scandinavian Simvistatin mals [77] [78] [79] . Numerous antioxidant vitamins have been evaluated 4. b-Adrenergic blockers through epidemiological studies for their association with atherosclerotic heart disease in humans, the strongest Hemodynamic forces, including circumferential stress, association of which has been with vitamin E (ashear stress and flexion stress, may cause disruption of a tocopherol). In male health professionals in the Health vulnerable plaque [93] According to Laplace's Law, Professionals Follow-up Study [80] and in female nurses in circumferential stress is directly related to a vessel's the Nurse's Health Study [81] who were free of diagnosed luminal diameter and intraluminal pressure and inversely cardiovascular disease, prospective follow-up revealed a to wall thickness [94] . Consequently, the level of circumstatistically significant lower risk of clinical coronary ferential stress is higher in plaques with mild as compared disease among those with a higher dietary intake of with severe stenosis due to the larger lumen [34, 93] partly vitamin E. A subgroup analysis of antioxidant vitamin explaining the fact that most acute coronary syndromes intake was performed in the Cholesterol Lowering Atherooccur in plaques with mild to moderate stenoses [95] . sclerosis Study (CLAS), a serial angiographic clinical trial Another explanation could be that plaques causing severe evaluating coronary artery disease progression in patients stenosis tend to have a higher fibrous and lower lipid randomized to placebo or colestipol and niacin. In this content than those producing less severe lesions analysis, subjects with a supplementary vitamin E intake of [28, 96, 97] . Circumferential stress is localized to the shoul-100 IU per day or greater demonstrated less coronary der regions of plaques with soft lipid-rich cores, the most artery lesion progression than did those with a supplecommon site of rupture. Plaques repeatedly subjected to mentary vitamin E intake less than 100 IU per day (mean mechanical stress may eventually weaken and rupture change in percent diameter stenosis of 20.8% vs. 2.0%, spontaneously, a phenomenon known as 'cap fatigue' respectively with a p value of 0.04) [82] . Dietary vitamin [37, 58] . E intake reduces LDL susceptibility to ex vivo oxidation in Triggers, including emotional stress, vigorous exercise humans [83] [84] [85] [86] . In experimental animals, including and cold weather, may precipitate plaque rupture by a nonhuman primates, vitamin E reduces the formation of surge in sympathetic activity causing a sudden increase in diet-induced atherosclerosis [87] [88] [89] .
blood pressure, heart rate, cardiac contractility and corIn the Cambridge Heart Antioxidant Study (CHAOS) onary blood flow [98] . b-Adrenergic blockers and an- [90] , 2002 patients with angiographically proven sympgiotensin converting enzyme inhibitors may reduce the tomatic coronary atherosclerosis were randomized to dietincidence of acute coronary syndromes by reducing the ary supplementation with vitamin E (400 or 800 IU) or hemodynamic forces that promote plaque rupture. placebo. After a median follow-up of 17 months, vitamin E Secondary prevention trials in patients with known treatment significantly reduced the primary composite coronary artery disease who have been treated with bendpoint of cardiovascular death and non-fatal myocardial blockers have shown a reduced incidence of reinfarction infarction (MI) by 47% ( p50.005).
and death. Meta-analysis of these secondary prevention The Alpha-tocopherol Beta-carotene Cancer Prevention trials has shown a 20% reduction in cardiac mortality, a Study (ATBC), investigating the effects of a-tocopherol 25% reduction in the incidence of reinfarction and a 30% (vitamin E) and b-carotene supplements on the incidence reduction in the incidence of sudden death [99] . b-Blockof lung cancer in male smokers, contained a substudy ade reduces the circumferential plaque stress by reducing evaluating the effects of these antioxidants on future blood pressure and blunting hypertensive pressure surges coronary events in 1862 men with a prior myocardial [100] . b-Blockers may also prevent plaque rupture by infarction. After a median of 5.3 years of follow-up, there increasing the ability of the plaque's fibrous cap to was no significant difference in the composite endpoint of withstand stress. The stress-bearing abilities of plaque vary fatal coronary heart disease and non-fatal myocardial with the frequency of the applied stress [101] . Because infarction among the groups randomized to vitamin E, plaque stiffness increases with heart rate, b-blockers may b-carotene, both vitamin E and b-carotene, or placebo increase plaque tensile strength by reducing heart rate [91] .
[100]. Besides the traditional antioxidants, HMG CoA reductase inhibitors may also reduce oxidized LDL levels by increasing the total antioxidant capacity of plasma. In the Kuopio Atherosclerosis Prevention Study (KAPS) [92] , 5. Angiotensin converting enzyme inhibitors pravastatin therapy for three years prolonged the lag time of LDL lipoproteins (a measure of oxidation resistance),
The SAVE (survival and ventricular enlargement) and increased plasma and LDL vitamin E levels, and improved SOLVD (studies on left ventricular dysfunction) Treatment overall LDL antioxidant capacity. Lovastatin and simvasand Prevention Trials have demonstrated a reduction in tatin have been shown to inhibit LDL oxidation and uptake cardiac events in patients with known coronary artery by macrophages in studies of shorter duration [74] .
disease who have been treated with an angiotensin convert-ing enzyme (ACE) inhibitor [102] [103] [104] . When the results heritable hyperlipidemic (WHHL) rabbit, ex vivo transfecof these three trials were combined, the overall risk tion of hepatocytes with the LDL receptor gene and reduction in myocardial infarction with long-term ACE reimplantation of the transduced hepatocytes into the liver inhibitor treatment was 23% [105] . The beneficial clinical resulted in stable expression of the LDL receptor and a effects cannot be based solely on the immediate hemoconsistent decrease in serum cholesterol for several months dynamic effects of ACE inhibitors since the improvement [118, 119] . In a pilot study of five patients with homoin the incidence of myocardial infarction did not become zygous familial hypercholesterolemia who were treated apparent until after six months and broadened thereafter with gene transfer of the LDL receptor, only two had a [106] . Other antihypertensive therapies do not provide as sustained moderate reduction in serum LDL cholesterol great a benefit as ACE inhibitors with regard to a reduction (|20%) [120] [121] [122] . Currently, gene therapy has limited in clinical cardiac events. In a meta-analysis of 14 randomclinical utility due to the variability in gene transfer and ized clinical trials of antihypertensive therapies, a 5-6 resultant gene expression. mmHg reduction in diastolic blood pressure was associated Gene transfer of apo-A1, the major protein component with a 14% reduction in coronary heart disease events. In of HDL, holds promise for achieving plaque stabilization contrast, in SOLVD, a reduction in diastolic blood pressure via removal of lipid, macrophage or both. Intravenous of 4 mmHg yielded a 23% reduction in myocardial injection of the apo-A1 gene in an adenoviral vector into infarction, indicating that benefits in addition to blood mice resulted in a transient increase in serum HDL to a pressure reduction were most probably involved [105, 107] .
level comparable to that shown to be protective in humans Several mechanisms have been hypothesized to explain [123] . When HDL is substantially increased therapeuticalthese results, including remodelling, anti-adrenergic efly, a decrease occurs in the number and activity of fects, antiatherosclerotic effects and / or antithrombotic macrophages and, presumably, in the occurrence of plaque effects [105] .
rupture [60] . There is evidence from animal experimentation that this benefit may, in part, also be related to plaque stabilization. Infusion of angiotensin into the coronary arteries of hyperlipidemic rabbits can produce endothelial damage 7. Promoters of extracellular matrix synthesis and can induce plaque rupture [108] . Use of ACE inhibitors in animal models of atherosclerosis has resulted Reduced collagen content in the fibrous cap may result not only in a decrease in the plaque area, but also a from decreased synthesis of extracellular matrix by smooth decrease in macrophage accumulation and cholesterol muscle cells (SMCs) and / or increased breakdown by content and an increase in the extracellular matrix of matrix-degrading proteases, thereby leading to thinning atherosclerotic plaques, all of which promote plaque and weakening of the fibrous cap, predisposing the plaque stabilization [109-112]. The ACE genotype DD, which is to rupture with hemodynamic or mechanical stresses [124] . associated with high circulating levels of ACE, was more Vascular SMCs synthesize the collagenous and noncolfrequent in patients with a prior history of myocardial lagenous portions of the extracellular matrix. Lack of infarction than in control subjects [113] . Potential mechasufficient smooth muscle cells to secrete and organize the nisms for the effect of ACE inhibitors on plaque stabilizamatrix in response to mechanical stress could render the tion include a reduction in arterial wall stress caused by fibrous cap more vulnerable to weakening by extracellular lower blood pressure or reduced levels of neurohumoral matrix degradation [18] . The extracellular matrix of activation, or their effect on protein synthesis influencing plaques is primarily composed of fibrillar collagens (types plaque composition [114] , since angiotensin II has been I and III collagen mainly, with smaller amounts of collagen shown to stimulate vascular smooth muscle cell growth types IV, V and VI), elastin, proteoglycans and microfibriland proliferation [115, 116] . lar proteins. While the synthesis and degradation of extracellular matrix proteins are slow in the normal artery, atherosclerosis and arterial injury lead to increased syn-6. Gene therapy thesis of many matrix components, including elastin, collagen types I and III, and several proteoglycans. In the Gene therapy strategies aimed at stabilizing vulnerable later stages of atherosclerosis, nonfibrillar collagen types plaques have thus far included decreasing plasma LDL and IV and V can be found in the fibrous cap [125] . For increasing plasma HDL. Transfer of the LDL receptor gene atherosclerotic lesions causing chronic stable ischemia due is possible for patients with familial hypercholesterolemia to the severity of the stenosis, excess matrix accumulation type IIb, a genetic deficiency in hepatic receptors for LDL is the primary mechanism of occlusion of the lumen. In cholesterol resulting in severe hypercholesterolemia and contrast, unstable lesions may fail to synthesize a sufficient premature coronary atherosclerosis [117] . In an animal mass of matrix to provide strength to the fibrous cap to model for familial hypercholesterolemia, the Watanabe prevent rupture [18] .
Fibrous caps that have ruptured not only have twice as these goals. Unfortunately, enhancement of matrix synmany macrophages as unruptured fibrous caps but also thesis may lead to increased plaque growth, resulting in have half as many SMCs [126] . Fewer SMCs may result in more severe stenosis and arterial occlusion and lead to inadequate extracellular matrix production and repair. more frequent restenosis after percutaneous coronary interReduced matrix synthesis may be the result of a decrease vention. in SMC numbers secondary to inhibition of proliferation, an increase in apoptosis, or the result of inhibition of matrix gene expression in the SMCs. Cytokines and 8. Inhibitors of plaque inflammation and extracellular growth factors in the plaque regulate the synthesis of matrix degradation matrix components. Transforming growth factor-b (TGFb) potently stimulates collagen synthesis, whereas
Increased matrix degrading activity associated with interferon-g (IFN-g) suppresses the expression of collagen vascular smooth muscle cells, macrophages and T lympho- [127] . IFN-g secreted by activated T lymphocytes not only cytes is a common finding in unstable atherosclerotic inhibits collagen gene expression in SMCs but also inhibits lesions and could lead to weakening of the fibrous cap and SMC proliferation and promotes apoptosis, possibly enresultant plaque rupture. There are three major pathways of hanced by interleukin-1b (IL-1b)-converting enzyme extracellular matrix degradation: the serine proteases, the (ICE) [128] [129] [130] [131] [132] [133] . An inverse relation exists between the cysteine proteases and the matrix metalloproteinases [18] . presence of T lymphocytes and interstitial collagen protein
The vast majority of evidence suggesting that matrix and mRNA [134] . Advanced human atheromas contain degradation may be involved in plaque rupture has focused regions rich in T lymphocytes that are in a chronic state of on the matrix metalloproteinases (MMPs). Plaque stabiliactivation, constitutively producing IFN-g [129] . Neighzation could be achieved through the inhibition of extracelboring SMCs express HLA-DR, indicating that they have lular matrix degradation either by preventing the accumubeen exposed to IFN-g [135, 136] . These data support the lation of macrophages and T lymphocytes in the atheroshypothesis that SMCs in the vicinity of activated T clerotic plaque or by inhibiting the proteolytic enzyme lymphocytes within the atheroma should exhibit a substancascade directly. tially reduced ability to synthesize interstitial collagen
The matrix metalloproteinase superfamily (Table 3 ) [134] . SMCs may therefore lack the ability to synthesize or includes three main classes: (a) the collagenases, which are effectively repair the surrounding extracellular matrix enzymes specialized in the initial cleavage of tightly [137] , enhancing the vulnerability of plaques to rupture.
coiled, native triple helical collagen that confer strength to Therefore, inflammatory cells not only participate in the fibrous cap, (b) the gelatinases, which can catalyze the matrix breakdown, but also inhibit matrix synthesis further breakdown of collagen fragments and (c) the [133, 138, 139] .
stromelysins, which can activate other members of the Apoptosis is common in atherosclerotic plaques and is MMP family and can degrade a broad spectrum of matrix virtually absent in non-atherosclerotic regions. Apoptosis constituents, including proteoglycan core proteins and occurs in SMCs subendothelially, within the fibrous cap elastin. A new group of MMPs, membrane-type MMPs and in the underlying media, which may destabilize the (MT-MMPs), has recently been identified. Instead of being plaque and promote rupture. Apoptosis is also common in soluble, MT-MMPs contain a transmembrane domain, thus macrophages and T cells subendothelially, in the fibrous attaching to the surface of the cell [140] . With the cap and in shoulder regions [132] . Subendothelially and exception of the MT-MMPs, the MMPs are secreted as deeper in the fibrous cap adjacent to regions with low inactive proenzymes or zymogens that must be activated cellularity, apoptotic SMCs are more frequent, suggesting by cleavage of the N-terminus. Endogenous inhibitors, that regions with low smooth muscle cellularity might be called tissue inhibitors of metalloproteinases (TIMPs), bind the result of pronounced cell reduction by apoptosis [132] .
to the active sites of MMPs and regulate their activity Human vascular SMCs in culture derived from atheros- [141, 142] . clerotic plaques were much more prone to cell death Multiple histologic studies have demonstrated that MMP characteristic of apoptosis than those derived from normal expression by vascular smooth muscle cells and macroarteries. The addition of insulin-like growth factor-1 (IGFphages is increased in human atherosclerotic plaques ( Fig.  1 ) and platelet-derived growth factor (PDGF) markedly 1) [143] . Increased stromelysin (MMP-3), interstitial colsuppressed apoptosis of both plaque-derived and normal lagenase (MMP-1) and gelatinase expression was noted in vascular SMCs, as did transfection with a retroviral vector human coronary atherosclerotic plaques [144] . Interstitial containing the human bcl-2 gene [131] .
collagenase expression was found at the borders of lipid Theoretically, inhibition of SMC apoptosis or promotion cores and in subsets of smooth muscle cells and endotheliof SMC proliferation and expression of matrix gene al cells in human carotid atherosclerotic plaques [145] . synthesis may lead to plaque stabilization. Manipulation of Interstitial collagenase colocalized with regions of circumcytokines and growth factors or a reduction in inflammaferential tensile stress in the fibrous cap of the atherostory cell infiltration may be potential methods to achieve clerotic plaque, which may play a role in the pathogenesis 
Gelatinases
Gelatinase A (MMP-2) Gelatins, collagen types IV, V, VII, X and XI, elastin, fibronectin, proteoglycan Gelatinase B (MMP-9)
Gelatins, collagen types IV and V, elastin, proteoglycan 
Unclassified

MMP-18 MMP-19
Adapted from Ye et al. [198] with permission.
of plaque rupture. The increased expression of MMP may from patients with acute ischemic syndromes with recent represent an adaptive response to mechanical stress, allowplaque rupture (unstable angina) and stable angina, but not ing the fibrous cap to remodel to a more structurally sound in normal internal mammary arteries. Intracellular localizaconfiguration, but this remodeling may transiently allow tion of gelatinase B, indicative of active synthesis, was the plaque to become vulnerable to rupture [146] [147] [148] . much more prevalent in the specimens from patients with Matrilysin (MMP-7) and metalloelastase (MMP-12) were unstable angina than from those with stable angina [150] . expressed in lipid-laden macrophages within human
The association of activated T lymphocytes and macroatherosclerotic lesions in carotid endarterectomy samples phages with plaque rupture was made after histologic but not in normal arteries [149] . The presence of gelatinase examination of the culprit lesions in 20 patients who died B (MMP-9) was noted in coronary atherectomy specimens of an acute myocardial infarction. T lymphocytes and macrophages predominated at the sites of plaque disruption (deep intimal rupture or superficial erosions). Adjacent SMCs, macrophages and lymphocytes expressed high levels of HLA-DR, an indicator of an active inflammatory reaction, which contrasted markedly with the low or absent expression of HLA-DR elsewhere in the fibrous cap [30] . Only IFN-g secreted by activated T lymphocytes induces the expression of HLA-DR, suggesting the presence of this cytokine at the sites of plaque rupture in humans [135] . Inflammation plays a key role in destabilizing the fibrous cap tissue and causing plaque rupture. wave myocardial infarctions) were shown to have at least a fourfold greater macrophage infiltration compared with plaques of patients with stable angina [151] . Increased macrophage density and reduced collagen content have been shown by in vitro mechanical testing to be associated with a reduced tensile strength [152] . When fibrous caps of human atherosclerotic plaques were exposed to human monocyte-derived macrophages in cell culture, there was biochemical evidence of increased collagen degradation as compared to cell-free culture medium, and this degradation was inhibited in the presence of an MMP inhibitor [124] . Vascular smooth muscle cells in culture constitutively express gelatinase A (MMP-2), which degrades nonfibrillar collagen and participates in cellular migration, as well as TIMPs [153, 154] . In the presence of cytokines, such as (MMP-9) [147, 153] . Taken together, the MMPs produced by vascular SMCs in culture can digest all the main components of the arterial wall extracellular matrix. Like lized and denatured and tend to aggregate and adhere to unstimulated SMCs in culture, SMCs of normal arterial surfaces, thereby limiting tissue penetration. They have tissue express MMP-2 and TIMPs. In contrast, SMCs of been used in mouse models of arthritis without convincing the atherosclerotic plaque, as well as cultured stimulated demonstration of effectiveness. The upregulation of TIMP SMCs, express, in addition, MMP-1, MMP-3 and MMP-9 production may be achieved with the administration of [147] .
cytokines, such as TGF-b or retinoids, but it is likely that Reduction in macrophage and T lymphocyte infiltration these compounds will have numerous side effects limiting and the resultant reduction in protease and cytokine release their use, since they are active in many cellular processes. may help stabilize plaques by decreasing extracellular Continued improvement in transfection techniques makes a matrix degradation and strengthening the fibrous cap. molecular approach to overexpressing the TIMP-1 or Lipid-lowering and antioxidants through their reduction in TIMP-2 genes more attractive, as demonstrated in nude oxidized LDL have been shown to reduce macrophage mice with reduction in local neoplastic invasion [141] . infiltration in experimental models [155] [156] [157] [158] [159] . If a Synthetic inhibitors of MMPs, including tetracyclineplaque's macrophage content is reduced, then the secretion derived antibiotics, anthracyclines and synthetic peptides, of collagen-degrading proteases will be reduced and, have been unimpressive in animal models and in clinical theoretically, may result in plaque stabilization. trials for rheumatoid arthritis. Retinoids and corticosteroids MMP inhibition also represents a potential therapeutic downregulate MMP transcription, however, they have strategy aimed at stabilizing plaques by reducing extracelproven ineffective in the treatment of restenosis after lular matrix degradation. Possible methods to achieve coronary angioplasty [141] . Moreover, not all of the MMP inhibition include (i) increasing the levels of natural matrix-degrading enzymes in the plaque are MMPs, and inhibitors (TIMPs) either by exogenous administration of the contribution of these non-MMPs to plaque destabilizarecombinant TIMPs or by an elevation in their local tion requires consideration. The long-term effects of MMP production, (ii) administering synthetic inhibitors, or (iii) inhibitor use also requires evaluation since MMPs are decreasing MMP production (Fig. 2) . TIMP-1 is syninvolved in many physiologic processes, including arterial thesized by most types of connective tissue cells, as well as remodelling, wound healing and angiogenesis. macrophages, and inhibits all members of the collagenase, Although MMPs can be activated by many factors in stromelysin and gelatinase classes of MMPs. It forms vitro, the fibrinolytic pathway, specifically plasmin, may high-affinity, irreversible, noncovalent complexes with the be one of the critical mediators for extracellular activation active form of the enzymes. TIMP-2 can also inhibit all of latent MMPs to their active form in vivo. Macrophagemembers of the collagenase, stromelysin and gelatinase and SMC-derived uPA and tPA, by acting on its cell classes of MMPs, especially gelatinase A. TIMP-1 is surface receptor, can thus generate plasmin near the cell highly inducible by cytokines and hormones, whereas surface, thereby facilitating activation of latent MMPs near TIMP-2 expression is largely constitutive, following the the cell surface, where they are less susceptible to the pattern of expression of gelatinase A [141] .
action of TIMP [160] [161] [162] . Local activation of the plasExogenously administered TIMPs are readily metabominogen activator system not only leads to enhanced extracellular membrane (ECM) degradation but also to cytes and macrophages, predisposing to thrombosis if activation of TGF-b, a powerful inducer of PAI-1 bioplaque rupture or erosion should occur [168] . synthesis in endothelial cells and SMCs, resulting in a decrease in PA activity. As mentioned previously, TGF-b also induces biosynthesis of extracellular matrix com-9. Macrolide antibiotics ponents. TGF-b or inhibitors of the plasminogen activators may represent a possible therapy aimed at achieving Epidemiologic data has suggested the association beplaque stabilization [162] .
tween infectious agents and coronary heart disease, espeThe CD40 pathway represents a possible signaling cially with Helicobacter pylori, Chlamydia pneumoniae mechanism through which macrophages and vascular and CMV [172, 173] . Potential causative mechanisms SMCs in atheroma can be induced to express matrixinclude both direct effects of the infectious agent on the degrading proteinases, resulting in plaque rupture. The arterial wall (endothelial injury or dysfunction, SMC CD40 receptor, a member of the TNF receptor family, is proliferation and local inflammation) and indirect effects located on the surface of SMCs and macrophages, and mediated in the circulation through chronic inflammation, activated T lymphocytes can express CD40 ligand, a TNFcross-reactive antibodies, or alterations in cardiovascular like molecule, on their cell surface [163] . Human monorisk factors (lipids, coagulation proteins, oxidative metabocytes and macrophages in culture were stimulated through lites or homocysteine) [173] . the CD40 receptor by either membranes from activated T
The strongest association between an infectious agent lymphocytes or by recombinant CD40 ligand, resulting in and coronary heart disease has been with Chlamydia increased expression of interstitial collagenase and
pneumoniae. Epidemiological studies demonstrate a constromelysin as well as tissue factor protein and activity that sistent association between elevated Chlamydia pneumoinitiates thrombosis [164] . The addition of IFN-g or niae antibody titres and myocardial infarction and corantibody to CD40 ligand inhibited the expression of these onary heart disease [174] [175] [176] [177] . Chlamydia pneumoniae MMPs by macrophages [164] . Stimulated human T lymelementary bodies and DNA have been found within phocytes also induced the expression of interstitial colatheromatous coronary arteries [178, 179] . Since laboratory lagenase, stromelysin, gelatinase B and activated gelatinase culture of this intracellular pathogen is difficult, elevations A in human vascular SMCs in culture via CD40 ligation.
in antibody titre may reflect new, reactivated or remote Recombinant human CD40 ligand induced the synthesis of infection. interstitial collagenase, stromelysin and gelatinase B on
The predictability of Chlamydia pneumoniae antibody vascular SMCs in culture and stimulated the expression of titres on future cardiovascular events and the effect of these enzymes to a greater extent than did maximally azithromycin (an antichlamydial macrolide antibiotic) on effective concentrations of TNF-a and IL-1b. IFN-g or future cardiovascular events were evaluated in 213 male neutralizing antibody to CD40 ligand inhibited the inducsurvivors of myocardial infarction. Fifty-nine patients were tion of MMPs by CD40 ligand in SMCs [165] . Interruption seronegative, 74 had intermediate titres and 80 were of CD40 signaling could provide a novel means of plaque strongly seropositive. Patients with strong persistent stabilization by preventing MMP-induced matrix degraseropositivity were randomized to either a short course of dation.
oral azithromycin therapy or placebo. Over a mean followSystemic evidence of acute inflammation, manifested by up period of one and a half years, the incidence of elevations in C-reactive protein (CRP) and serum amyloid cardiovascular events (defined as nonfatal MI, cardiovascu-A protein (SAA), is more prevalent in patients with lar death, unstable angina requiring either intravenous unstable angina or acute myocardial infarction compared to anti-anginal therapy, coronary angioplasty or urgent corthose with stable angina and represents an independent onary bypass surgery) increased with increasing predictor of worse outcome with higher rates of death, MI Chlamydia pneumoniae antibody titre. Treatment with and myocardial revascularization [166] [167] [168] [169] [170] [171] . The elevation azithromycin in the seropositive patients reduced the in acute phase reactants may reflect intrinsic inflammation incidence of cardiovascular events fivefold, reaching the and tissue injury within the atherosclerotic plaque or may risk of those seronegative patients. Patients receiving reflect inflammation or tissue injury elsewhere in the body azithromycin therapy were more likely to experience a that promotes atherogenesis and plaque instability [168] . reduction in IgG Chlamydia pneumoniae antibody titres Ischemia-induced endothelial damage, oxidized LDL, imthan those in the placebo group. The authors concluded mune complexes and infection are all potential causes of that an increased Chlamydia pneumoniae antibody titre in vascular injury and an acute-phase response [167] . For post-MI patients may be a predictor for further adverse example, Helicobacter pylori, Chlamydia pneumoniae and cardiovascular events, and administration of a short course cytomegalovirus (CMV) infections are associated with of azithromycin in the seropositive patients may lower this increased CRP and possibly coronary heart disease. CRP risk, possibly by acting against Chlamydia pneumoniae. also stimulates the production of tissue factor by monoAzithromycin, by suppressing or eradicating infection, may tunately, no animal model has yet been developed to 
